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Abstract
Recent findings suggest that modulation of ion channels might be implicated in some of the clinical effects of coxibs,
selective inhibitors of cyclooxygenase-2 (COX-2). Celecoxib and its inactive analog 2,5-dimethyl-celecoxib, but not rofecoxib,
can suppress or augment ionic currents and alter functioning of neurons and myocytes. To better understand these
unexpected effects, we have recently investigated the mechanism of inhibition of human Kv2.1 channels by a highly
selective COX-2 inhibitor SC-791. In this study we have further explored the SC-791 action on ion channels and heartbeat in
Drosophila, which lacks cyclooxygenases and thus can serve as a convenient model to study COX-2-independent
mechanisms of coxibs. Using intracellular recordings in combination with a pharmacological approach and utilizing
available Drosophila mutants, we found that SC-791 inhibited voltage-activated K
+ and L-type Ca
2+ channels in larval body-
wall muscles and reduced heart rate in a concentration-dependent manner. Unlike celecoxib and several other K
+ channel
blockers, SC-791 did not induce arrhythmia. Instead, application of SC-791 resulted in a dramatic slowing of contractions
and, at higher concentrations, in progressively weaker contractions with gradual cessation of heartbeat. Isradipine,
a selective blocker of L-type Ca
2+ channels, showed a similar pattern of heart arrest, though no prolongation of contractions
was observed. Ryanodine was the only channel modulating compound of those tested additionally that was capable of
slowing contractions. Like SC-791, ryanodine reduced heart rate without arrhythmia. However, it could not stop heartbeat
completely even at 500 mM, the highest concentration used. The magnitude of heart rate reduction, when SC-791 and
ryanodine were applied together, was smaller than expected for independent mechanisms, raising the possibility that SC-
791 might be interfering with excitation-contraction coupling in Drosophila heart.
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Introduction
Selective inhibitors of cycloxygenase-2 (COX-2) are important
non-steroidal anti-inflammatory drugs (NSAIDs), widely pre-
scribed for treatment of arthritis and acute pain. Four coxibs,
celecoxib (Celebrex), etoricoxib (Arcoxia), rofecoxib (Vioxx), and
valdecoxib (Bextra) were developed and marketed as NSAIDs with
reduced gastrointestinal side effects. However, increased risk of
cardiovascular side effects, including myocardial infarction,
cardiac arrhythmias and stroke, led to eventual withdrawal of
rofecoxib and valdecoxib in 2004 and 2005, respectively.
Several studies have demonstrated that celecoxib can interact
with various molecular targets, including cellular and enzymatic
mechanisms other than cyclooxygenases. For instance, the drug
inhibits carbonic anhydrases with nanomolar affinity [1], while at
low micromolar concentrations it alters functioning of voltage-
activated Na
+,K
+ and Ca
2+ channels [2,3,4,5], induces cytotox-
icity towards cardiomyocytes [6], triggers apoptosis and blocks cell
cycle progression [1,7].
We have previously shown that celecoxib can inhibit K
+
channels in fruit flies and mammals, reducing beating rate and
inducing arrhythmia in Drosophila heart and cultured rat ventric-
ular cardiomyocytes [8]. Similarly, celecoxib inhibits voltage-
activated Na
+ and K
+ channels in isolated rat retinal neurons with
a strong suppression of spontaneous spiking activity [9]. These
effects occur independently from inhibition of cyclooxygenases
and involve rapid, direct and reversible action of celecoxib on ion
channels (coxibs inhibit COX-2 irreversibly). It has been shown
that celecoxib inhibits Kv2.1 and Shab channels via modification
of gating at lower concentrations and channel block at higher
concentrations [5,10]. Also, celecoxib and its inactive analog, 2,5-
dimethyl-celecoxib (DMC), but not rofecoxib, can acutely and
reversibly up-regulate currents through Kv7.5 (KCNQ5) cardiac
channels in the isolated rat mesenteric artery myocytes and A7r5
rat aortic smooth muscle cells, while simultaneously inhibiting
other currents [4]. In addition, celecoxib was shown to inhibit
Kv1.5, Kv4.3, Kv7.1, and hERG channels and to alter action
potential duration in mouse and guinea pig cardiomyocytes
[11,12].
A surprising variety of coxibs’ molecular targets requires further
research to better understand possible risks associated with these
important drugs. We have recently examined effects of SC-791 on
human Kv2.1channels expressed in HEK-293 cells [13]. The
compound, used in the experimental setting [14,15,16,17], has
been selected for two reasons, an extremely high selectivity for
COX-2 (SC-791 inhibits hCOX-2 with an IC50 of 4 nM and
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28,500), and its structural similarity to celecoxib [13]. The drug
inhibits Kv2.1 via gating modification, but, unlike celecoxib, it
does not induce channel block. In this study we have examined
effects of SC-791 on ion channels and heartbeat in Drosophila
melanogaster. The fruit fly, a widely used model organism,
apparently lacks cyclooxygenases [8] and thus is very well suited
for basic research on the COX-2-independent action of coxibs.
Here we show that SC-791 inhibited voltage-activated K
+ and L-
type Ca
2+ channels and reduced heart rate in concentration-
dependent manner. Unlike celecoxib and several other K
+ channel
blockers, SC-791 did not induce arrhythmia. Instead, application
of SC-791 resulted in a dramatic slowing of contractions and, at
higher concentrations, in progressively weaker contractions with
a gradual cessation of heartbeat.
Results
Effects of SC-791 on ionic currents in larval muscles
Several ionic currents have been previously identified in
Drosophila larval body-wall muscles: T-type and L-type Ca
2+
currents [19,20,21], two calcium-activated K
+ currents, and three
voltage-activated K
+ currents [22,23]. The latter include Shaker
channels, conducting fast activating and inactivating IA; Shab
channels, mediating relatively slow delayed rectifier IKS; and
rapidly activating IKF with unknown molecular basis [24]. In this
study we have assessed effects of SC-791 on four major currents:
L-type current and three K
+ currents, IA,I KS, and IKF (Fig. 1A,
2A). These currents can be separated by electrophysiological,
pharmacological and genetic means. The L-type current can be
isolated by recording in the presence of K
+ channel blockers (TEA,
4-AP and quinidine) from a holding potential (HP) of 240 mV (to
inactivate T-type Ca
2+ channels) with Ba
2+ ions as charge carrier
(to prevent muscle contractions and to additionally block K
+
channels) [20,24]. The IKF can be recorded from the Shab strain in
the presence of 4-AP to block the IA; the IKF can be completely
abolished by 200 mMC d
2+ in the external solution [8], allowing
recording of IKS from the wild-type larvae. The IA can be recorded
from wild-type animals with Cd
2+ (to inhibit IKF) and 100 mM
quinidine (to selectively inhibit the IKS) in the bath or from the
Shab in the presence of Cd
2+ only.
SC-791 inhibited L-type Ca
2+ channels in a concentration-
dependent manner with an IC50 of 54 mM for the peak currents
(Fig. 1). The L-type current in the presence of SC-791 was
characterized by slower kinetics of activation and inactivation,
suggesting modification of channel gating or closed-channel block,
the latter can be associated with slowing of activation and
inactivation kinetics due to partial unblock of blocked channels at
positive voltages.
Figure 2A-C demonstrates that the main effect of SC-791 on the
IKS was acceleration of inactivation, though the reduction in the
peak IKS indicates that the drug might also alter the activation
kinetics, similarly to its action on the human Kv2.1 [13]. The effect
of SC-791 on IKS was measured at 50 ms after the onset of
a voltage pulse to +40 mV and at the end of 500 ms pulses. The
IC50s for inhibition of IKS for these two time points were 74 and
21 mM, respectively (Fig. 2D). The effect of SC-791 on IKF was
relatively small with a noticeable inhibition observed only at
100 mM and higher concentrations (Fig. 2E–F); 100 mM SC-791
failed to alter the IA altogether (Fig. 2G).
Effects of SC-791 on heartbeat
The larval heart has a pacemaker region and a non-pacemaking
myocardium [25]. Electrical activity in the heart is driven by
myogenic pacemaker located in the caudal-most segment of the
heart [26]. Larval heart tube myocytes do not express sodium
channels; instead, depolarization is provided by L-type Ca
2+
channels as in the body-wall muscles [27], though L-type Ca
2+
channels are apparently not involved in the pacemaker activity
[27]. Among potassium channels, involvement of Shab, KCNQ
and eag in Drosophila heartbeat has been documented previously
[8,27,28,29]. SC-791 inhibited heartbeat in dose-dependent
manner with an EC50 (the effective concentration to alter
a functional parameter by 50%) of 30 mM (see example in Fig. 3A);
drug effects developed slowly and usually reached a relatively
steady-state level around 20 min after a rapid wash-in (Fig. 3D).
They included a reduced heart rate and heart wall displacement
amplitude and prolonged contraction duration. During contrac-
tion, the maximal displacement of heart wall was observed at
160610 ms after initiation of contraction in control and at
254617 ms in the presence of 30 mM SC-791. The character of
SC-791 effect on heartbeat was distinct from that of celecoxib. In
the presence of celecoxib, irregularity of heartbeat with a signifi-
cant variation in both the peak-to-peak intervals and the
amplitude of heart wall displacement was observed, especially at
concentrations above 3 mM [8] (Fig. 3C). In contrast, analysis of
variation in peak-to-peak intervals and in amplitude of heart wall
displacement indicated that SC-791 did not increase heartbeat
irregularity significantly (Fig. 3B). In addition, the effects of SC-
791 on heartbeat were largely irreversible.
At 50 mM and higher concentrations, SC-791 progressively
reduced heart rate, increased duration of heart contractions and
decreased contraction amplitude up to the point when heartbeat
could no longer be detected: at 100 mM SC-791 heartbeat ceased
after 20 min exposure in 3 out of 6 cases, and at 300 mM heartbeat
ceased in 3 out of 3 cases after 10 min exposure. Figure 4A
demonstrates an example of a developing failure of heartbeat at
Figure 1. Inhibition of L-type Ca
2+ channels by SC-791. L-type
currents in larval body-wall muscles in control (A) and in the presence of
30 mM SC-791 (B) were elicited by 500 ms voltage pulses between 260
and +40 mV in 10 mV increments from a holding potential (HP) of
240 mV; averaged traces are shown. (C) SC-791 slowed activation of L-
type Ca
2+ channels. Activation time constants were determined by
fitting the rising part of the current with a single exponential function;
(n), number of experiments. (D) Dose-response relation for inhibition of
the peak L-type current by SC-791 at 210 mV; the curves in this and
following dose-response relations represent fits to Hill equation.
doi:10.1371/journal.pone.0038759.g001
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of the initial phase of contraction. Once again, this pattern was
different from the effects of higher concentrations of celecoxib,
which usually involved a sudden halt of beating, often against the
background of severe arrhythmia [8].
In a previous study we have shown that effects of celecoxib on
heart rate in Drosophila primarily result from inhibition of Shab
channels [8]. Inhibition of other channels, including L-type Ca
2+
channels, by low micromolar concentrations of celecoxib has been
negligible. In an attempt to understand what could account for the
strikingly different character of SC-791 action, we tested if it can
be reproduced through inhibition of several ion channels known
for their role in Drosophila heart. Because SC-791 inhibited L-type
Ca
2+ channels with an IC50 of 54 mM, we first tested effects of
isradipine on heartbeat. 10 mM isradipine, a selective dihydropyr-
idine blocker of L-type Ca
2+ channels [19], blocked L-type Ca
2+
channels in larval body-wall myocytes nearly completely without
any effect on K
+ currents. At higher concentrations, isradipine was
able to block K
+ current with an IC50 around 30 mM for the
currents at the end of a 500 ms pulse to +40 mV and with a much
smaller effect on the peak currents, indicating open-channel block
(data not shown). Effects of exposure of heart preparation to 1 or
3 mM isradipine strongly resembled the effects of SC-791:
a gradual decrease in heart rate with decreasing amplitude of
contractions (Fig. 4B). However, in contrast to SC-791, isradipine
did not prolong contractions (Fig. 4C–D). Several other K
+
channel blockers and toxins were tested, including TEA (in-
discriminate K
+ channel blocker; at submillimolar concentrations
it can block Kv3), quinidine (blocks Kv2 and other channels), 4-AP
(Kv1), heteropodatoxin (Kv4), linopirdine (Kv7), E-4031 (erg or
Kv11), paxilline (KCa1), and apamin (KCa2). Some of these
compounds (TEA, quinidine [8], and linopirdine) altered heart
rate and induced arrhythmia but none were able to slow
contractions (data not shown).
Figure 2. Inhibition of K
+ currents by SC-791. (A) Schematic representation of three voltage-activated K
+ currents. The average IKS in control (B)
and in the presence of 30 mM SC-791 (C) in the wild-type larvae; currents were evoked by 500 ms voltage pulses between 240 and +40 mV from a HP
of 280 mV in 10 mV increments in the presence of 200 mM CdCl2 in bath solution to block the IKF; the IA can be seen in panels B, C, E, F in the
beginning of each trace; it was not removed as it did not obscure the effects of SC-791 on other currents. (D) Dose-response relations for inhibition of
the IKS by SC-791 at 50 ms after the onset (open circles) and at the end of a voltage pulse to +40 mV (closed circles); the number of experiments
varied from 5 to 12. The average IKF in control (E) and in the presence of 100 mM SC-791(F)i nShab mutant larvae; the currents were elicited by 500 ms
voltage pulses between 240 and +40 mV from a HP of 280 mV in 10 mV increments; the number of experiments for each condition was 8. (G) SC-
791 did not affect the IA; the currents were recorded from Shab larvae as in the panels (B–C) in the presence of 200 mM CdCl2 to block the IKF; the
number of experiments for each condition was 9.
doi:10.1371/journal.pone.0038759.g002
SC-791, Ion Channels and Heartbeat in Drosophila
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38759SC-791 and Ca
2+ release from intracellular stores
Prolongation of contractions in the presence of SC-791 could
not be explained by a reduced Ca
2+ influx through partially
inhibited L-type Ca
2+ channels (isradipine blocked L-type
channels but did not prolong contractions), nor by slowing of L-
type current activation (the activation time constants at the
voltages above 220 mV did not exceed 3 ms (Fig. 1C), i.e. they
were two orders of magnitude smaller than the duration of the
actual contraction (160 ms in control); it should also be noted that
Ca
2+ channel recordings but not heartbeat measurements were
performed using Ba
2+ as a charge carrier, which slows channel
kinetics substantially. On the other hand, it is known that changes
in intracellular Ca
2+ dynamics can alter the velocity of muscle
contractions. For example, disruption of ryanodine receptor
(RyR)-mediated Ca
2+ release in RyR loss-of-function mutant flies
dramatically slows the muscle contraction velocity and reduces
heart rate to 25% of control [30]. Similarly, we found that
thapsigargin, inhibitor of sarcoplasmic reticulum Ca
2+-ATPase
(SERCA), which is responsible for replenishment of Ca
2+ stores in
the sarcoplasmic reticulum, can dramatically reduce heart rate
and prolong contractions (unpublished observations); this obser-
vation is consistent with the previously published report on the
crucial role of SERCA in Drosophila heartbeat [31]. Moreover, low
micromolar concentrations of Cd
2+ were also able to alter
heartbeat drastically, transforming individual contractions into
prolonged spastic events with contracted heart muscle unable to
relax for many seconds (unpublished observations). We therefore
hypothesized that slowing of contractions in the presence of SC-
791 could result from modulation of Ca
2+ release from sarcoplas-
mic reticulum. As previous studies have described interaction of
celecoxib with numerous ion channels and other targets, and this
Figure 3. Effects of SC-791 on heartbeat. Traces represent the relative displacement of an edge of the larval heart in the experiments with SC-
791 (A) or celecoxib (C); heartbeat was video recorded immediately before drug application, at 18–20 min after wash-in of 30 mM SC-791 or at 8–
10 min after application of 10 mM celecoxib, and at 8–10 min after washing the drug out; (B) depicts heartbeat irregularity in the presence of 30 mM
SC-791; the coefficient of variation (CV) was calculated as described previously [8]; the number of experiments was 8. (D) Average heart rate is shown
for 6–10 larvae before drug application, after rapid wash-in of 3 mM, 10 mM, 30 mM, or 100 mM SC-791 (horizontal bar), and after the wash-out;
treatment with 0.5% Me2SO, the maximum concentration of Me2SO used with SC-791, did not change the heart rate significantly. (E) A dose-response
curve for the effect of SC-791 on heart rate is shown.
doi:10.1371/journal.pone.0038759.g003
Figure 4. Heartbeat disruption by SC-791 and isradipine.
Development of heartbeat stoppage in the presence of 50 mM SC-791
(A)o r3mM isradipine (B). The corresponding averaged contraction
waveforms demonstrate similarities (decrease in amplitude) and
differences (prolongation of contraction) between the effects of SC-
791 (C) and isradipine (D); each waveform is an average of 10 to 20
individual contraction waveforms.
doi:10.1371/journal.pone.0038759.g004
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and can modulate several dissimilar ion channels, it appeared
possible that SC-791 could interact with Ca
2+ release channels,
specifically with the RyR Ca
2+ release channel, a major compo-
nent of excitation-contraction (EC) coupling in myocytes, which
mediates Ca
2+ release in response to activation of dihydropyridine
(DHP) receptors L-type Ca
2+ channels. We tested this hypothesis
by examining effects of ryanodine on heartbeat separately and in
combination with SC-791.
Ryanodine is a highly selective modulator of the RyR Ca
2+
release channels. At nanomolar concentrations ryanodine pro-
motes opening of the RyR, at low micromolar concentrations it
locks the RyR in the half-open state, and at concentrations around
100 mM it completely and irreversibly inhibits the RyR [30]. In
our experiments, 100 mM ryanodine instantly and irreversibly
reduced heart rate with a remarkable prolongation of contractions
(Fig. 5A). Interestingly, 10, 100, and 500 mM ryanodine reduced
heartbeat to a similar degree, by 6164, 6262, and 6365%,
respectively, suggesting that all these concentrations are in the
saturation range. As even 500 mM ryanodine, the highest
concentration used, could not stop heartbeat, these results also
indicated that RyR-mediated Ca
2+ release is an important but not
the essential aspect of EC coupling in the larval heart. This
conclusion is consistent with the previously published observations
[30].
If SC-791 and ryanodine interacted with the same molecular
target, i.e. inhibited the RyR, then the total effect of two
compounds applied together would be smaller than expected
from the Bliss independence criterion (BIC) E
BI
AB. The BIC is
derived from probability theory as a measure of total effect of two
pharmacological agents acting via independent mechanisms. The
equation for the zero-interaction effect is E
BI
AB=E A+EB2EA*EB,
where EA and EB are the fractional single-agent effects of
compounds A and B at given concentration [32,33]. If the
experimentally determined effect of a combination of two drugs is
smaller than the BIC, then antagonistic interaction between the
compounds may be at play; if it is higher, synergism is likely [34].
Based on our experimental results, we calculated the BIC for the
combined effects of 100 mM ryanodine (62% heart rate decrease)
and 30 mM SC-791 (52% heart rate decrease) and compared it to
the experimentally measured effect of the combination of the
drugs (Fig. 5). The value of BIC was 0.82, i.e. if the drugs
suppressed heartbeat via independent mechanisms, 82% heart rate
reduction would be expected in the presence of 100 mM ryanodine
and 30 mM SC-791. When solution containing 30 mM SC-791
and 100 mM ryanodine was applied after 20 min exposure to
100 mM ryanodine (Fig. 5A, C), the combined effect at the end of
40 min long exposure was the decrease in heart rate by 7263%.
However, when the two drugs were applied after 20 min exposure
of heart preparation to 30 mM SC-791, the total reduction in heart
rate was 6865% (Fig. 5B, D). Specifically, 30 mM SC-791 reduced
heart rate by 5262% when used as a single-agent (Fig. 5D) versus
2565% when SC-791 was applied after exposure to 100 mM
ryanodine (P,0.001, ANOVA, Fig. 5C). The respective values for
ryanodine were 6263% (Fig. 5C) and 4864% (P,0.02, Fig. 5D).
Interestingly, when 100 mM ryanodine and 30 mM SC-791 were
applied simultaneously without pre-exposure of heart to any drug,
the heart rate was inhibited by only 6464%. Figure 5E shows
average values of difference between the BIC of 0.82 and the
experimentally determined reduction in heart rate in the presence
of the two drugs (for three different orders of drug application As
the reduction in heart rate was less than the BIC value in all these
cases, our results suggested that SC-791 directly or indirectly
interfered with the RyR-mediated Ca
2+ release.
However, if SC-791’s influence on the contraction was
mediated only via the RyR, then no additional effects of the SC-
791 on heartbeat would be observed in the presence of 100 mM
ryanodine, a saturating concentration almost completely inhibiting
the receptor. Yet two such effects were observed: a further
reduction in heart rate and slowing of contractions (Fig. 5). While
the former could be associated with the consequences of inhibition
of L-type Ca
2+ channels as illustrated in the action of isradipine,
the latter could not. Figure 5F shows that addition of SC-791 to
ryanodine-supplemented bath solution had further decelerated
heart wall displacement: from 210 ms to reach the maximal
displacement in control, to 645 ms in the presence of ryanodine,
and then to 745 ms after adding in 30 mM SC-791.
Two other substances, thapsigargin and Cd
2+, could disrupt
heartbeat and slow down contractions, however, it was not
possible to investigate pharmacological independence of their and
SC-791’s effects due to rapid and irreversible deterioration of
heartbeat after their application.
Figure 5. Effects of ryanodine on heartbeat. Typical examples of
heartbeat in control, after 20 min application of either 100 mM
ryanodine (A)o r3 0mM SC-791 (B) alone followed by 20 min exposure
to a solution containing both 100 mM ryanodine and 30 mM SC-791,
and after the wash-out. (C, D) Time course of the average heart rate in
the experiments described in the panels (A) and (B), respectively; dotted
lines indicate the value of BIC (82% heart rate inhibition) (see Results);
panels (C) and (D), averages of 7 and 6 experiments, respectively. (E) Bar
plot illustrates differences between the BIC of 0.82 and the
experimentally determined total fractional reduction in heart rate for
three experimental conditions: when SC-791/ryanodine was applied
after (1) exposure to ryanodine alone, (2) exposure to SC-791 alone, and
(3) without pre-exposure of the preparation to any compound. (F) Bar
plot summarizes effects of ryanodine and SC-791 on the duration of
heart contraction when the chemicals were applied in different order as
in the panels (A) and (B).
doi:10.1371/journal.pone.0038759.g005
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Because of the significance of selective COX-2 inhibitors in
contemporary therapeutics, it is important to investigate their
action on ion channels and the resulting functional changes at the
cellular and organ levels. Recent research demonstrates that low
micromolar concentrations of celecoxib and its analogs can modify
functioning of a broad range of ion channels via gating
modification or channel block, and alter neuronal and myocytes
functioning [2,3,4,9]. Because different ion channels can be
modulated by coxibs via dissimilar mechanisms with different
outcomes (reduction or augmentation of a current) and because
specialized cells express specific compositions of ion channels, the
end effects of the drugs on cell performance are likely to differ even
between cells executing the same function. Indeed, Macias and
coauthors have shown that celecoxib can prolong action potential
duration in mouse cardiac myocytes while shortening it in guinea
pig cardiac myocytes [13]. An additional layer of complexity to
this picture is added by possible interaction of coxibs with other
molecular targets that could alter cell functioning but are not
related to ion channels, such as the coxibs’ main receptor, COX-2,
or carbonic anhydrases [1,7]. Thus, although apparently no single
‘ideal’ model organism for studying ion channel-related effects of
coxibs exists, the well-studied Drosophila, which conveniently lacks
cyclooxygenases, provides a good experimental setting for basic
research in this direction.
This study demonstrates that even highly structurally similar
coxibs, celecoxib and SC-791, can dramatically differ in their
effects on Drosophila heartbeat. Evidence suggests that these
differences originate from dissimilar profiles of ion channel
inhibition. Celecoxib inhibits Shab channels in body-wall muscles
with an IC50 of 10 mM for the currents at the end of a 500 ms
pulse to +40 mV (an IC50 of 37 mM for the current at 50 ms after
the start of the voltage pulse) [8]. At higher concentrations,
celecoxib inhibited L-type Ca
2+ channels (an IC50 of 74 mM for
the peak current, unpublished observations) and also the IKF
(about 50% inhibition at 100 mM) [8]. Accordingly, the drug has
reduced larval heart rate with an EC50 of 11 mM; its effects on
heartbeat are very similar to those observed in Shab flies, with
a decrease in heart rate, strong arrhythmia and an abrupt ceasing
of beat observed at higher concentrations. In contrast, SC-791
inhibited Shab current with IC50so f2 1mM (the end of 500 ms
pulses) and 74 mM (at 50 ms), and L-type current with an IC50 of
54 mM. The heart rate was reduced with an EC50 of 30 mM, but
in a different manner: with a much slower development of the
effect, without substantial arrhythmia, virtually irreversibly, and
with prolongation of contractions.
Thus, at lower concentrations (,50 mM) celecoxib mainly
affects the IKS, whereas SC-791 – the L-type current and the IKS.
This difference can explain the absence of arrhythmia in the
presence of SC-791: celecoxib and SC-791 perturb the balance of
ionic currents during action potential in dissimilar ways. By
inhibiting K
+ channels with a higher potency than Ca
2+ channels,
celecoxib might induce arrhythmia by compromising repolariza-
tion in the pacemaker cells without measurably affecting de-
polarization. SC-791, on the other hand, inhibited both Shab and
L-type Ca
2+ channels with a similar potency, which could result in
less misbalanced depolarizing and repolarizing currents and,
therefore, trigger no arrhythmia (although certain distortions in
the action potential waveform would inevitably arise even in such
case – from increase in the membrane time constant due to
inhibition of conductances, and from non-uniform voltage-de-
pendencies of ion channel inhibition). Such scenario could also
explain the differences in the character of heart pauses and stops:
blocking repolarization, celecoxib often stops heartbeat abruptly
(with a similarly sudden resumption of beating), whereas SC-791
stopped heartbeat after a gradual decrease in the beating rate and
contraction amplitude, and without pauses.
Regarding possibly different effects of celecoxib and SC-791 on
pacemaker activity, two aspects should be emphasized. First, the
ion channels regulating the pacemaker activity in the larval heart
appear to be not the same as the ion channels providing for
depolarization and signal propagation in the myocardium [27,35].
One of the key differences is that the L-type Ca
2+ channels are not
important for the function of the pacemaker, while OPQ-type
Ca
2+ channels appear to be critical [27]. It is not known if
celecoxib and SC-791 can modulate the latter channels in
Drosophila, but celecoxib blocked similar channels in rat PC12
cells with lower affinity than the L-type Ca
2+ channels [2],
suggesting that celecoxib might alter the balance between
depolarizing and repolarizing currents even more drastically in
the pacemaker cells than in the myocardium. Secondly, although
heart rate is regulated by the pacemaker cells presumably lacking
the L-type Ca
2+ channels, application of relatively low concentra-
tions of isradipine (Fig. 4B, D) was nevertheless capable of reducing
heart rate, indicating that either some other pacemaker’s ion
channels are affected by the drug or myocardium itself is involved
in heart rate regulation.
Another explanation for the lack of arrhythmia in the presence
of SC-791 could be that as the body-wall muscle and heart
channellomes are not the same, the drugs could differentially
inhibit other ion channels expressed in heart but not in body-wall
muscles. Two such channels associated with arrhythmic heartbeat
are KCNQ and erg. Experiments in mammalian experimental
systems have demonstrated that celecoxib can inhibit these and
many other channels [2,3,4,5]. For instance, application of
linopirdine, a highly selective KCNQ inhibitor, reduced Drosophila
heart rate and induced arrhythmia (unpublished observations);
similar observations of dysrhythmic heartbeat were made in the
KCNQ knock-out flies [28].
Our experiments with high concentrations of isradipine,
a selective L-type Ca
2+ channel blocker and an anti- hypertensive
medicine, strongly suggest that inhibition of L-type Ca
2+ channels
is a major determinant of SC-791 action on heartbeat. However,
what could be the mechanism behind the gradual weakening of
contractions?
Reduction in the L-type current is more than just a decrease in
a depolarizing current, because Ca
2+ entering the cell during the
action potential is essential not only for maintaining depolariza-
tion, but also for excitation-contraction coupling [36] and
replenishment of Ca
2+ stores in the sarcoplasmic reticulum (SR).
In the presence of a L-type Ca
2+ channel blocker, reduced influx
of Ca
2+ through these channels will lower the overall Ca
2+ load in
the lumen during the action potential, which can itself compromise
the contraction directly or via reduced Ca
2+ induced Ca
2+ release.
Intracellular Ca
2+ is subsequently removed back into the SR by
SERCA, and ejected from the cell by the sodium-calcium
exchanger or the plasma membrane calcium ATPase. As the
share of luminal Ca
2+ coming from the outside would be lower
than in control, the Ca
2+ removal mechanisms might dispropor-
tionally wash out Ca
2+ coming from the SR, thus gradually
depleting the sarcoplasmic Ca
2+ store and impairing contractions.
Interestingly, the notion that coxibs can interfere with muscle
contractions by blocking L-type Ca
2+ channels is supported by
experiments with celecoxib in a different experimental system, rat
aortic smooth muscle A7r5 cells, where celecoxib inhibits L-type
Ca
2+ channels while augmenting the repolarizing KV7.5 current.
There, inhibition of L-type Ca
2+ channels eliminates the arginine
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2+ spiking and causes concentration-
dependent dilation of mesenteric arteries [4].
While inhibition of L-type Ca
2+ channels by SC-791 could
explain most of the observed changes in heartbeat, it could not
explain the slowing of contraction velocity. Our experiments with
ryanodine suggest that prolongation of contractions in the
presence of SC-791 might result from the altered EC coupling,
that is, mainly, but not exclusively, from SC-791’s interference
with the RyR Ca
2+ release pathway. Application of a saturating
concentration of ryanodine (100 mM) could eliminate the rapid
component of Ca
2+ release from intracellular stores, dramatically
slowing the contraction velocity and reducing the heart rate. When
SC-791 was supplemented to the bath already containing
ryanodine, the resultant changes in heartbeat were smaller than
expected for independent mechanisms. Although reduction in the
Ca
2+ influx due to inhibition of L-type Ca
2+ channels by SC-791
could in principle interfere with the RyR-mediated Ca
2+ induced
Ca
2+ release and slow down the contractions, experiments with
isradipine ruled out this possibility. Therefore, it is possible that
SC-791 interacted with RyR directly or through one of its
regulatory pathways [37]. Importantly, when SC-791 was applied
together with ryanodine after a prolonged exposure to ryanodine,
the velocity of contractions was further reduced (Fig. 5), suggesting
that SC-791 could also target the remaining slow Ca
2+ release
mechanism(s). As a side note, because the effects of ryanodine were
also irreversible, such interaction might help explain the irrevers-
ibility of SC-791 action on heartbeat (Fig. 3, 5).
In conclusion, this study demonstrates how relatively small
differences in molecular action on ion channels of two similar
compounds, celecoxib and SC-791, can translate into drastic
dissimilarities of drug effects at the organ level, and illustrates the
utility of Drosophila as a suitable experimental system for basic
research on effects of coxibs resulting from inhibition of ion
channels.
Materials and Methods
Heart beat recording
Strains of Drosophila melanogaster were maintained at 21uC. CS
was used as the wild-type strain. Shab denotes the Shab
3, Drosophila
Kv2 null-mutant strain [38]. Larval heart beat was monitored at
21uC using a previously described preparation and video
recording procedure [8]. In brief, heart rate (HR) was allowed
to stabilize for about 5 minutes after the end of dissection. During
experiment, HR was counted for 5 min before drug application,
for 20 min in the presence of the drug, and for 10 min after
washing out the drug. Preparations demonstrating any significant
heartbeat irregularity prior to drug application were discarded.
Video recordings of heartbeat were made at a resolution of
6406480 pixels at 30 frames/s and data were analyzed as
described previously [8]. In brief, a single portion of a video
recording (usually 2–20 pixels wide) with clear and unobscured
heart wall movement was selected from each video recording for
further analysis. This area of interest was transformed into a series
of images frame-by-frame using VirtualDub 1.6.5 video editor
software by Avery Lee. Location of the wall in each frame was
then determined using custom-made software. Resulting wave-
forms were used to obtain amplitudes and beat-to-beat intervals.
This provided a sufficient number (60–300) of events for statistical
analysis, which was performed using Microsoft Excel and IgorPro
data analysis packages. Coefficient of variation was used as
a measure of heartbeat regularity [8].
Electrophysiology
Voltage-activated K
+ currents and L-type Ca
2+ channel
currents were recorded from larval body-wall muscles (fiber 12)
using two-microelectrode voltage-clamp technique as described
previously [24,39]. The voltage electrode was filled with 2.5 M
KCl and the current electrode with a 3:1 mixture of KCl and
potassium citrate. Recording solution for K
+ currents contained (in
mM): NaCl (77.5), KCl (5), MgCl2 (4), NaHCO3 (2.5), trehalose
(5), sucrose (115), and HEPES (5), pH 7.1 [24]. Recording solution
to record L-type currents was in addition supplemented with
10 mM BaCl2, 20 mM TEA, 1 mM 4-AP, and 100 mM
quinidine. SC-791 was purchased from Calbiochem (EMD
Chemicals, Inc., 346 NJ) and all other chemicals from Sigma-
Aldrich Co. (St. Louis, Missouri USA). Celecoxib was purified as
described previously [10]. Because of relatively rapid rundown of
ionic currents, each cell was stimulated by an experimental
protocol only once.
All experiments were performed at 21uC on a temperature-
controlled headstage using a circulating water bath from Forma
Scientific. In figures, error bars indicate 6 s.e.m. Statistical
analysis was performed using a single factor ANOVA test. All
values are means 6 SEM; (*): P,0.05, (**): P,0.01.
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